Processa Pharmaceuticals, Inc. Development Stage Entities, Stock Issued, Shares, Issued for Noncash Consideration (Deprecated 2015-01-31)
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Processa Pharmaceuticals, Inc. development stage entities, stock issued, shares, issued for noncash consideration (deprecated 2015-01-31) for fiscal 2014 was 1.10M shares.
| Period end | Development Stage Entities, Stock Issued, Shares, Issued for Noncash Consideration (Deprecated 2015-01-31) 3 month | Development Stage Entities, Stock Issued, Shares, Issued for Noncash Consideration (Deprecated 2015-01-31) 12 month |
|---|---|---|
| 2014-12-31 | 1.10M shares 10-K · filed 2015-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |